IN8BIO INC (INAB) Stock Price, Forecast & Analysis
USA - NASDAQ:INAB - US45674E2081 - Common Stock
INAB Key Statistics, Chart & Performance
The current stock price of INAB is 1.7 USD. In the past month the price decreased by -20.56%. In the past year, price decreased by -82.16%.
INAB Latest News, Press Relases and Analysis
INAB Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 25 | 417.40B | ||
| AMGN | AMGEN INC | 15.43 | 181.72B | ||
| GILD | GILEAD SCIENCES INC | 15.46 | 157.14B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.58 | 109.42B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.79 | 80.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 855.65 | 57.20B | ||
| INSM | INSMED INC | N/A | 42.01B | ||
| NTRA | NATERA INC | N/A | 31.65B | ||
| BIIB | BIOGEN INC | 10.47 | 25.70B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.99 | 21.48B | ||
| INCY | INCYTE CORP | 15.9 | 19.93B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.10B |
Related stock screener links
About INAB
Company Profile
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company is headquartered in New York City, New York and currently employs 18 full-time employees. The company went IPO on 2020-11-12. The firm is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
Company Info
IN8BIO INC
Empire State Building, 350 5Th Avenue, Suite 5330
New York City NEW YORK US
CEO: William Ho
Employees: 18
Phone: 16466006438
IN8BIO INC / INAB FAQ
What does IN8BIO INC do?
IN8bio, Inc. operates as a clinical stage biopharmaceutical company, which focuses on developing novel therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. The company is headquartered in New York City, New York and currently employs 18 full-time employees. The company went IPO on 2020-11-12. The firm is focused on the discovery, development and commercialization of gamma-delta T cell-based immunotherapies for cancer patients. Gamma-delta T cells are a specialized population of T cells that possess properties, including the ability to differentiate between healthy and diseased tissue. Its lead program, INB-100, is in an ongoing investigator-sponsored Phase I clinical trial of acute myeloid leukemia (AML). Its other product candidates include INB-200, INB-300, INB-500 and INB-600. INB-200 is a genetically modified, autologous gamma-delta T cell product to be administered in combination with the current standard-of-care chemotherapy in newly diagnosed glioblastoma (GBM). INB-300 is a preclinical program focused on developing unique non-signaling gamma-delta T cell based chimeric antigen receptor (nsCAR)-enabled DeltEx product candidates with a focus on targeting liquid tumors and extracranial solid tumors.
What is the stock price of IN8BIO INC today?
The current stock price of INAB is 1.7 USD. The price increased by 6.92% in the last trading session.
Does INAB stock pay dividends?
INAB does not pay a dividend.
How is the ChartMill rating for IN8BIO INC?
INAB has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the PE ratio for INAB stock?
IN8BIO INC (INAB) does not have a PE ratio as the earnings reported over the last twelve months were negative (-5.39).
How many employees does IN8BIO INC have?
IN8BIO INC (INAB) currently has 18 employees.
What is the ownership structure of IN8BIO INC (INAB)?
You can find the ownership structure of IN8BIO INC (INAB) on the Ownership tab.
INAB Technical Analysis
INAB Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to INAB. Both the profitability and financial health of INAB have multiple concerns.
INAB Financial Highlights
Over the last trailing twelve months INAB reported a non-GAAP Earnings per Share(EPS) of -5.39. The EPS increased by 76.04% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -123.33% | ||
| ROE | -156.77% | ||
| Debt/Equity | 0.01 |
INAB Forecast & Estimates
10 analysts have analysed INAB and the average price target is 50.24 USD. This implies a price increase of 2855% is expected in the next year compared to the current price of 1.7.